Sponsor Check › Person
Named as an officer, director or promoter on SEC Form D filings · NY, PA, CA, IL, CT, WA, DE · Nov 5, 2009 → Aug 12, 2024
Data last updated Oct 23, 2026, 5:45 PM ET · Courts (RECAP) last checked: Oct 24, 2026, 2:19 AM ET · SEC enforcement last checked: covered by the index scan as of Oct 24, 2026, 2:50 AM ET
Liam Ratcliffe is listed as an executive officer and director on 26 SEC Form D filings by 11 issuers between Nov 2009 and Aug 2024. Largest by amount reported sold: Halda Therapeutics, LLC (New Haven, CT — other health care — 2021–2024; $126.5M reported sold to 20 investors), Climb Bio, Inc. (Wellesley Hills, MA — biotechnology — 2020–2024; $120M reported sold to 22 investors), Aptinyx Inc. (Evanston, IL — pharmaceuticals — 2016–2017; $70M reported sold to 63 investors), ARVINAS, INC. (New Haven, CT — biotechnology — 2015–2019; $55M reported sold to 22 investors), Afferent Pharmaceuticals, Inc. (San Mateo, CA — pharmaceuticals — 2009–2015; $55M reported sold to 17 investors) and 6 more (all listed below).
What this means That is a lot of deals — 11 separate companies raised money with this person listed as executive officer and director, over about 15 years. Across those companies the filings report $508.1M sold in total.
Listed alongside Andrew Levin (6 shared filings), Vijay Lathi (6 shared filings), Tim Shannon (5 shared filings), Adam J. Rosenberg (4 shared filings), Jeani Delagardelle (4 shared filings) and 85 others.
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Liam. Each name links to their own page.
The issuers belong to 3 sponsor groups: New Leaf (2 issuers, $0 reported sold, 2018), New Leaf (2 issuers, $20M reported sold, 2014–2016) and Arvinas (2 issuers, $36M reported sold, 2013–2019).
What this means This person is listed across more than one sponsor team; each group page shows that team's full track record.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AK, AL, AR, AZ, CA, CT, DE, FINRA, GA, HI, ID, IL, KS, KY, LA, MA, MD, ME, MI, MO, MS, MT, NASAA, NC, ND, NH, NM, NV, OK, OR, PA, RI, SC, SD, TN, TX, VT, WA, WI, WV, WY) — none found.
What this means Nothing turned up where we looked (3 sources). That does not prove there is nothing — it means none was found in those sources on that date.
We compared 26 public filings for Liam Ratcliffe and found 15 differences, 3 worth asking the sponsor about: Liam Ratcliffe appears on 5 deals that stopped filing before reaching their target; Paid seller listed without a CRD number: Gold Eagle Enterprises Limited; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.
Community search for Liam Ratcliffe has not run yet — it is joining a line of 24,268 names; searches run around the clock at the hosts' allowed rate. Searched so far: 638 names.
Community comments are quoted as written by their authors. Sources searched: BiggerPockets forums (via DuckDuckGo, Brave, Bing and BiggerPockets search) and Reddit (search feed + public archive).
Five things investors ask first. Items still in human review are counted, not shown.
None found in sources searched — federal courts (CourtListener / RECAP), checked Oct 24, 2026
Sources searched: CourtListener bulk data (RECAP dockets as of 2026-09-30; recall-first rule 10-24) — federal district + bankruptcy courts State courts: not covered (one-tap state court links under Look further). PACER: not searched. · Last checked Oct 24, 2026, 2:19 AM ET.
State courts: not covered (one-tap state court links under Look further). No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.
None found in sources searched — SEC enforcement releases (index scan as of Oct 24, 2026, 2:50 AM ET) · state securities regulators: VA (crawled Oct 23, 2026)
SEC enforcement searched: SEC litigation releases and administrative proceedings — respondent names in the sec.gov index titles (30,205 releases, 1995-09-19 to 2026-10-23); release text is read only to confirm a candidate. Names that appear only in the body of a release are not found. — Searched SEC litigation releases and administrative proceedings (1995→ / 2007→) (30,205 records as of Oct 24, 2026, 2:50 AM ET) — nothing matched Liam Ratcliffe..
State securities regulators: Securities regulators searched (3,318 actions): AZ Corporation Commission Securities Division (411 actions, 2017–2026), CA DFPI (25 actions, 2007–2024; listing starts 2002 — 16 of 12,159 DFPI respondent pages read so far; sponsor-name matches are read first), DE DOJ Investor Protection Unit (257 actions, 1987–2026), TX State Securities Board (586 actions, 2006–2026), WA DFI (2,039 actions, 2001–2026) — last crawled Oct 23, 2026, 9:57 PM ET. No machine-readable public listing today for CO, FL, IA, IN, MN, NE, NJ, NY, OH, UT, VA (see docs/state-regulators.md).
None found in sources searched — federal bankruptcy courts (CourtListener / RECAP), checked Oct 24, 2026
Sources searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not covered (one-tap state court links under Look further). PACER: not searched (RECAP only). · Last checked Oct 24, 2026, 2:19 AM ET.
State courts: not covered (one-tap state court links under Look further). No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.
Comparisons cover issuers and sponsor groups — see the issuer pages under Deals
15 differences found between the filings for Liam Ratcliffe — 3 worth asking about (compared 26 filings on Oct 24, 2026)
United States Bankruptcy Court, D. New Jersey docket "PNC Bank v. Litchman" filed Oct 23, 2000, closed Feb 27, 2002. Manuel Litchman (listed on the same filings) is listed as Defendant ("Litchman"). Our match estimate: 70%.
What this means A bankruptcy filing was found. Many are old or personal and have nothing to do with the deal — but ask what it was and when it closed.
CuraSen Therapeutics, Inc. (last filing Sep 18, 2024; $27,249,994 sold of $54,499,989); New Leaf Biopharma Opportunities II, L.P. (last filing Apr 16, 2018; $0 sold of $200,000,000); New Leaf Ventures IV, L.P. (last filing Apr 16, 2018; $0 sold of $275,000,000); New Leaf Growth Fund I, L.P. (last filing Feb 18, 2016; $20,000,000 sold of $200,000,000); New Leaf Ventures III, L.P. (last filing Dec 3, 2014; $0 sold of $375,000,000). Each has no filing in more than two years and reported under half its target sold.
What this means An issuer whose last filing is more than two years old and reported under half its target sold. The raise may have closed early or quietly stopped. Ask what happened to each.
Gold Eagle Enterprises Limited is listed as receiving sales compensation on 1 filing (Apr 16, 2018) with no FINRA CRD number given.
What this means People paid to sell securities normally hold a FINRA registration with a CRD number. Without one we cannot look them up on BrokerCheck. Ask who they are and whether they are registered.
The filing says the first sale was Sep 18, 2018. The Form D was filed Jan 25, 2019 — 129 days later. The rule: a Form D is generally due within 15 days after the first sale, so this one is 114 days past that.
What this means A late notice is common and carries no penalty by itself. It is worth asking the sponsor why the paperwork lagged.
The filing says the first sale was Oct 16, 2020. The Form D was filed Nov 3, 2020 — 18 days later. The rule: a Form D is generally due within 15 days after the first sale, so this one is 3 days past that.
What this means A late notice is common and carries no penalty by itself. It is worth asking the sponsor why the paperwork lagged.
No amendment in the last 12 months on an offering that may still be open — Halda Therapeutics, LLC (latest filing May 24, 2024) · No amendment in the last 12 months on an offering that may still be open — Halda Therapeutics, LLC (latest filing Dec 10, 2021) · No amendment in the last 12 months on an offering that may still be open — Climb Bio, Inc. (latest filing Nov 3, 2020) · No amendment in the last 12 months on an offering that may still be open — CuraSen Therapeutics, Inc. (latest filing Jan 25, 2019) · No amendment in the last 12 months on an offering that may still be open — Aptinyx Inc. (latest filing May 19, 2016) · and 2 more
What this means SEC rules expect a yearly amendment while an offering is still going. Ask the sponsor which of these raises have closed.
The Dec 3, 2014 filing says an indefinite amount offered; the Dec 4, 2014 Form D/A says $200,000,000.
What this means The target raise changed. Raising the cap is common when a deal grows; ask whether the extra money has the same terms and use.
The Nov 5, 2009 filing says $150,000 offered; the Dec 18, 2009 Form D says $23,000,000.
What this means The target raise changed. Raising the cap is common when a deal grows; ask whether the extra money has the same terms and use.
listed as "Liam Ratcliffe" on 24 filings (from Nov 5, 2009), and "Liam T. Ratcliffe" on 2 filings (from Apr 16, 2018).
What this means Same person, written differently — a middle name or suffix left off, or spelled another way. It is normal, but check that the full legal name matches your subscription documents.
"Pharmaceuticals" (Nov 3, 2020 to May 28, 2021); then "Biotechnology" (Jul 2, 2024 to Jul 2, 2024).
What this means The issuer described its business differently on different forms. Often it is just a different box ticked; sometimes the deal itself changed. Ask which business your money is in.
"Biotechnology" (Dec 10, 2021); then "Other Health Care" (May 24, 2024 to Aug 12, 2024).
What this means The issuer described its business differently on different forms. Often it is just a different box ticked; sometimes the deal itself changed. Ask which business your money is in.
"Other Health Care" (Nov 5, 2009 to Dec 18, 2009); then "Pharmaceuticals" (Jul 14, 2015).
What this means The issuer described its business differently on different forms. Often it is just a different box ticked; sometimes the deal itself changed. Ask which business your money is in.
This page covers filings where the address state is NY or PA or CA or IL or CT or WA or DE. A separate record, "Liam Ratcliffe" with address state MA, is listed on 1 filing — most recently by Unum Therapeutics Inc. (Jun 25, 2015). Both records have filings in the same period (Jun 25, 2015).
What this means Two records with one name were active at the same time. That can be one person listing different company addresses, or two different people. We keep them apart until a filing ties them together. Check both pages before you decide.
Address moved from Madison, CT to Boston, MA — Halda Therapeutics, LLC · Address moved from Redmond, WA to Wilmington, DE — Climb Bio, Inc. · Address moved from New York, NY to Madison, CT — Halda Therapeutics, LLC · Address moved from New York, NY to New Haven, CT — ARVINAS, INC. · Address moved from New Haven, CT to New York, NY — ARVINAS, INC. · and 1 more
What this means Businesses move. If you were told one city and the forms say another, ask which is current.
NY on 14 filings (Nov 5, 2009 to Aug 12, 2024); PA on 2 filings (Dec 3, 2014 to May 7, 2015); CA on 2 filings (Jul 14, 2015 to Jan 25, 2019); IL on 2 filings (May 19, 2016 to Dec 21, 2017); CT on 2 filings (Jul 19, 2019 to May 24, 2024); WA on 2 filings (Nov 3, 2020 to May 28, 2021); DE on 2 filings (Jul 2, 2024 to Jul 2, 2024).
What this means The address on a Form D is usually the company's, not the person's home, so this often just reflects different companies. It can also mean a move. Nothing wrong by itself.
What is compared: every Form D and D/A we hold for this subject, side by side — filing dates vs. first-sale dates (the 15-day rule), amendment timing on open offerings (the yearly-amendment expectation), amounts sold, investor counts, offering amounts and minimums across amendments, industry and size bands, addresses, how each person's name and role is written, paid sellers' CRD numbers, and (for groups) where the member companies were formed and sit. Everything is as filed by the issuer; the SEC does not check it. Differences are common and usually have ordinary explanations — we show both values, the dates, and the source so you can ask. As of Oct 24, 2026.
0 of 24 offerings report sales commissions; 1 reports finder's fees totalling $25,000; 0 report proceeds to related persons. (includes amounts the issuer reported as estimates)
| Offering (latest filing) | Sales commissions | Finder's fees | To insiders | Paid to sell it | Source |
|---|---|---|---|---|---|
| Aug 12, 2024 D Halda Therapeutics, LLC File 021-521220 | $0 | $0 | $0 No amounts other than ordinary course employment compensation is being paid to officers and managers. | None listed on this filing | EDGAR ↗ |
| Jul 2, 2024 D Climb Bio, Inc. File 021-517682 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Jul 2, 2024 D Climb Bio, Inc. File 021-517684 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| May 24, 2024 D Halda Therapeutics, LLC File 021-514297 | $0 | $0 | $0 No amounts other than ordinary course employment compensation is being paid to officers and managers. | None listed on this filing | EDGAR ↗ |
| Dec 10, 2021 D Halda Therapeutics, LLC File 021-424482 | $0 | $0 | $0 No amounts other than ordinary course employment compensation is being paid to officers and managers. | None listed on this filing | EDGAR ↗ |
| May 28, 2021 D Climb Bio, Inc. File 021-401012 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Nov 3, 2020 D Climb Bio, Inc. File 021-379616 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Jul 19, 2019 D ARVINAS, INC. File 021-344713 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Jan 25, 2019 D CuraSen Therapeutics, Inc. File 021-331349 | $0 | $0 | $0 (est.) | None listed on this filing | EDGAR ↗ |
| Apr 16, 2018 D New Leaf Biopharma Opportunities II, L.P. File 021-310283 | $0 | $0 | $0 (est.) An affiliate of the General Partner will receive a fee for management services. Amount to be paid, number of years to be paid, and extent to be paid out of adjusted gross proceeds unknown at this time. | None listed on this filing | EDGAR ↗ |
| Apr 16, 2018 D New Leaf Ventures IV, L.P. File 021-310285 | $0 | $25,000 (est.) | $0 (est.) An affiliate of the General Partner will receive a fee for management services. Amount to be paid, number of years to be paid, and extent to be paid out of adjusted gross proceeds unknown at this time. | Gold Eagle Enterprises Limited no CRD number reported | EDGAR ↗ |
| Apr 5, 2018 D ARVINAS, INC. File 021-309449 | $0 | $0 | $0 No payments other than ordinary course employment compensation is being paid to officers or managers. | None listed on this filing | EDGAR ↗ |
| Dec 21, 2017 D Aptinyx Inc. File 021-301461 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| May 19, 2016 D Aptinyx Inc. File 021-263486 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Feb 18, 2016 D New Leaf Growth Fund I, L.P. File 021-257743 | $0 | $0 | $0 (est.) An affiliate of the General Partner will receive a fee for management services. Amount to be paid, number of years to be paid, and extent to be paid out of adjusted gross proceeds unknown at this time. | None listed on this filing | EDGAR ↗ |
| Oct 23, 2015 D ARVINAS, INC. File 021-249974 | $0 | $0 | $0 No payments other than ordinary course employment compensation is being paid to officers or directors. | None listed on this filing | EDGAR ↗ |
| Jul 14, 2015 D Afferent Pharmaceuticals, Inc. File 021-243651 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| May 7, 2015 D Neuronetics, Inc. File 021-239365 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Dec 4, 2014 D/A New Leaf Growth Fund I, L.P. File 021-229361 | $0 | $0 | $0 (est.) An affiliate of the General Partner will receive a fee for management services. Amount to be paid, number of years to be paid, and extent to be paid out of adjusted gross proceeds unknown at this time. | None listed on this filing | EDGAR ↗ |
| Dec 3, 2014 D Neuronetics, Inc. File 021-229343 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Dec 3, 2014 D New Leaf Ventures III, L.P. File 021-229360 | $0 | $0 | $0 (est.) An affiliate of the General Partner will receive a fee for management services. Amount to be paid, number of years to be paid, and extent to be paid out of adjusted gross proceeds unknown at this time. | None listed on this filing | EDGAR ↗ |
| Jan 3, 2013 D Neuronetics, Inc. File 021-189354 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| May 23, 2011 D Neuronetics, Inc. File 021-160217 | $0 | $0 | $0 | None listed on this filing | EDGAR ↗ |
| Dec 18, 2009 D Afferent Pharmaceuticals, Inc. File 021-135875 | $0 | $0 | $0 (est.) | None listed on this filing | EDGAR ↗ |
Counts come from Form D Items 12–15 on the filings in our index (latest filing per offering; one offering = one SEC file number; an amendment updates its offering rather than adding one). "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates. "Paid to sell it" = sales compensation recipients named on that filing (Item 12), each linked to FINRA BrokerCheck when a CRD number is reported.
Counted across every filing this person is listed on (latest filing per offering, per issuer).
Every issuer that named Liam Ratcliffe on a Form D, newest first. A Form D is the notice a company files after it starts selling a private investment.
Raised $126.5M from 20 investors (100% of the $126.5M target) as of the latest filing. Liam is listed as director on 3 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Other Health Care / 506(b) (4,189 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $120M from 22 investors (100% of the $120M target) as of the latest filing. Liam is listed as director on 4 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $55M from 22 investors (100% of the $32.5M target) as of the latest filing. Liam is listed as director on 3 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $27.2M from 11 investors (50% of the $54.5M target) as of the latest filing. Liam is listed as director.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(c) (163 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
No sales reported yet as of the latest filing. Liam is listed as executive officer.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
No sales reported yet as of the latest filing. Liam is listed as executive officer.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $70M from 63 investors (100% of the $70M target) as of the latest filing. Liam is listed as director on 2 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $20M from 1 investor (100% of the $20M target) as of the latest filing. Liam is listed as executive officer on 3 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $55M from 17 investors (100% of the $55M target) as of the latest filing. Liam is listed as director on 3 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Raised $34.3M from 23 investors (100% of the $34.3M target) as of the latest filing. Liam is listed as director on 4 filings for this deal.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Other Health Care / 506(b) (4,189 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
No sales reported yet as of the latest filing. Liam is listed as executive officer.
Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Separate person records under the same name, not combined with this page. Each line says whether it shares an issuer with this record.
Officers, directors, promoters and management entities named on the same filings, as of Oct 23, 2026, 5:45 PM ET. Showing the 40 with the most shared filings.
Listed on the same filings as Liam Ratcliffe. Their page shows their other deals.
Listed on the same filings as Liam Ratcliffe. Their page shows their other deals.
Listed on the same filings as Liam Ratcliffe. Their page shows their other deals.
Listed on the same filings as Liam Ratcliffe. Their page shows their other deals.
Listed on the same filings as Liam Ratcliffe. Their page shows their other deals.
Listed on the same filings as Liam Ratcliffe. Their page shows their other deals.
Listed on the same filings as Liam Ratcliffe. Their page shows their other deals.
Andrew Levin is on 21 issuers in total — a repeat sponsor. Their page lists every one.
Vijay Lathi is on 14 issuers in total — a repeat sponsor. Their page lists every one.
Tim Shannon is on 5 issuers in total — a repeat sponsor. Their page lists every one.
Adam J. Rosenberg is on 6 issuers in total — a repeat sponsor. Their page lists every one.
Listed on the same filings as Liam Ratcliffe. Their page shows their other deals.
Listed on the same filings as Liam Ratcliffe. Their page shows their other deals.
Kevin Bitterman is on 24 issuers in total — a repeat sponsor. Their page lists every one.
P. Sherrill Neff is on 5 issuers in total — a repeat sponsor. Their page lists every one.
Listed on the same filings as Liam Ratcliffe. Their page shows their other deals.
Listed on the same filings as Liam Ratcliffe. Their page shows their other deals.
Sean Cassidy is on 6 issuers in total — a repeat sponsor. Their page lists every one.
Arthur M. Pappas is on 11 issuers in total — a repeat sponsor. Their page lists every one.
Kevin Starr is on 9 issuers in total — a repeat sponsor. Their page lists every one.
Kush Parmar is on 17 issuers in total — a repeat sponsor. Their page lists every one.
Listed on the same filings as Liam Ratcliffe. Their page shows their other deals.
Listed on the same filings as Liam Ratcliffe. Their page shows their other deals.
Jesse Treu is on 10 issuers in total — a repeat sponsor. Their page lists every one.
David Neafus is on 11 issuers in total — a repeat sponsor. Their page lists every one.
Listed on the same filings as Liam Ratcliffe. Their page shows their other deals.
Listed on the same filings as Liam Ratcliffe. Their page shows their other deals.
Listed on the same filings as Liam Ratcliffe. Their page shows their other deals.
Listed on the same filings as Liam Ratcliffe. Their page shows their other deals.
Listed on the same filings as Liam Ratcliffe. Their page shows their other deals.
Listed on the same filings as Liam Ratcliffe. Their page shows their other deals.
Mitchell S. Bloom is on 12 issuers in total — a repeat sponsor. Their page lists every one.
One team, 2 deal companies. Liam Ratcliffe is listed on 2 of them.
Issuers are grouped when their Form D filings share related persons, a management entity or a business address (automatic match from the filings). "Listed" marks the issuers that name Liam Ratcliffe.
One team, 2 deal companies. Liam Ratcliffe is listed on 2 of them.
Issuers are grouped when their Form D filings share related persons, a management entity or a business address (automatic match from the filings). "Listed" marks the issuers that name Liam Ratcliffe.
One team, 2 deal companies. Liam Ratcliffe is listed on 1 of them.
Issuers are grouped when their Form D filings share related persons, a management entity or a business address (automatic match from the filings). "Listed" marks the issuers that name Liam Ratcliffe.
A shared address can mean the same team, a shared office building or a registered agent. It is a lead, not a conclusion.
None of the 11 issuers this person is listed on appears in Form ADV (searched 24,962 advisers as of Oct 2, 2026). A person is never an adviser firm; Form ADV is checked for the issuers and the management companies they are listed with.
Searched SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 (51,358 records as of Oct 23, 2026, 8:41 PM ET) — nothing matched this name.
Property records are matched to companies only, never to individuals, so none are matched to Liam Ratcliffe by design. Searched property records in Hillsborough County FL (Clerk recorded-document index Oct 14, 2026 to Oct 15, 2026 + FL DOR 2026 ownership roll), Miami-Dade County FL (FL DOR 2026 ownership roll), Harris County TX (HCAD 2026 ownership roll), Dallas County TX (DCAD 2026 ownership roll), New York City ACRIS documents and PLUTO ownership rows already retrieved for other issuers, Cook County IL sale and ownership rows already retrieved for other issuers (814,874 records as of Oct 23, 2026, 8:59 PM ET) for the 11 issuers this person is listed on — nothing matched.
Websites and social links of the issuers Liam Ratcliffe is listed on: none on file. No website or social profile named in ARVINAS, INC.'s SEC filings (Form C, Reg A, Form ADV; checked Oct 24, 2026). Web search for this name: #231,255 of 374,652 in line (1,207 issuers searched so far). One-tap searches: Look further ↓
One-tap searches on sites we do not index ourselves, with the name pre-filled (New Haven, CT). Each opens in a new tab; what you find there is not verified by PartnerFacts.
No corrections have been requested for this page.
Free. Logged with status: received → under review → fixed / confirmed with source.
If this is you or your firm, add a sourced explanation next to any fact. Reviewed before publishing.
Members get an email when Liam Ratcliffe appears on a new Form D, or when a court case or SEC action is matched to them. See plans →